Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau".
Hum Vaccin Immunother
; 20(1): 2351669, 2024 Dec 31.
Article
in En
| MEDLINE
| ID: mdl-38757563
ABSTRACT
The first-line therapy of metastatic renal cell carcinoma (mRCC) has revolutionized with the approval of immune checkpoint inhibitors (ICIs) in combination with or without tyrosine kinase inhibitors (TKIs). The choice among the many different immuno-combinations (ICI-ICI or ICI-TKI) is challenging due to the lack of predictive factors. The different shapes of the Kaplan-Meier survival curves (e.g. "banana-shaped curves") have raised many questions on the long-term survival benefit. Here, we analyzed the factors that could have impacted the different long-term survival, including the prognostic factors distribution (IMDC score), histological factors (sarcomatoid features, PD-L1 expression), and treatment characteristics (mechanism of action, duration, discontinuation rate). This overview highlights the factors that should be considered in the first-line setting for the patients' therapeutic choice and prognostic assessment. They are also fundamental parameters to examined for head-to-head studies and real-life, large-scale studies.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Immune Checkpoint Inhibitors
/
Kidney Neoplasms
Limits:
Humans
Language:
En
Journal:
Hum Vaccin Immunother
/
Hum. vaccin. immunother. (Online)
/
Human vaccines & immunotherapeutics (Online)
Year:
2024
Document type:
Article
Affiliation country:
Italia
Country of publication:
Estados Unidos